ASRT — Assertio Holdings, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1808665 ·
Last close
$23.46
Market Cap
$151.60M
52W High
$23.47
52W Low
$11.20
ADV30
423,766
Next earnings
2026-08-10
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 9,933,000 7,222,000 -18,470,000 -18,856,000 211,299,000 33,713,000 135,667,000
Dec 2025 13,542,000 10,276,000 -9,149,000 -11,927,000 266,970,000 10,229,000 173,018,000
Sep 2025 49,459,000 35,805,000 12,902,000 11,445,000 319,775,000 38,500,000 213,972,000
Jun 2025 29,222,000 18,545,000 -8,035,000 -16,352,000 273,780,000 47,086,000 180,482,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,182,000
Investing CF
$-11,988,000
Financing CF
$-189,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.86
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-703,499,000
Inventory
$24,120,000
Receivables
$120,110,000
ST Investments
$53,176,000
EBIT TTM
$-27,340,000
Pretax Income TTM
$-29,940,000
Interest Exp TTM
$2,600,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$102,158,000
EBITDA
$3,827,000
Free Cash Flow
$7,750,750
Enterprise Value
$120,152,880
Total Cash
$71,569,000
Total Debt
$40,313,000
Shares Out
6,462,180
Trailing EPS
$-5.55
Book Value
$11.73
ROE
-38.8%
ROA
-5.7%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 118,713,000 -17,223,000 -30,375,000 266,970,000 173,018,000 -28,182,000
Dec 2024 124,961,000 -18,783,000 -21,581,000 284,732,000 163,651,000 26,408,000
Dec 2023 152,069,000 16,041,000 -331,942,000 286,419,000 148,416,000 49,604,000
Dec 2022 156,234,000 58,092,000 109,625,000 413,913,000 188,188,000 78,598,000
Dec 2021

TTM Snapshot

Revenues TTM
$124,515,000
NetIncome TTM
$-274,554,000
OpCashFlow TTM
$0
Assets (Latest)
$284,732,000
Forward EPS
$2.58

Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.00 · spot: $23.46 · call volume: 49 · put volume: 1

Peers — same industry

TickerNameMarket CapLastDaily %
OGI ORGANIGRAM GLOBAL INC. $152.04M $1.08
MIST Milestone Pharmaceuticals Inc. $150.64M $1.21
TTRX Turn Therapeutics Inc. $150.58M $5.05
SLNCF Silence Therapeutics plc $150.21M $1.06
ORMP ORAMED PHARMACEUTICALS INC. $149.38M $3.65

News headlines (Yahoo Finance, 1h cache)

Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
2026-05-13 12:00 · Yahoo
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
2026-05-13 10:27 · Yahoo
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
2026-05-08 12:00 · Yahoo
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
2026-05-05 13:00 · Yahoo
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
2026-05-05 10:56 · Yahoo
How The Assertio Holdings (ASRT) Story Is Shifting With The Garda Takeover And Valuation Anchor
2026-05-05 07:12 · Yahoo
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
2026-05-04 12:00 · Yahoo
Are Medical Stocks Lagging Assertio (ASRT) This Year?
2026-04-30 13:40 · Yahoo
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
2026-04-29 20:30 · Yahoo
Assertio Provides Update on Garda Therapeutics Tender Process
2026-04-21 21:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.